Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China · Delayed Price · Currency is CNY 3.680
-0.010 (-0.27%)
Apr 29, 2026, 3:00 PM CST
SHA:600664 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 15,965 | 15,964 | 16,119 | 15,400 | 13,755 | 12,741 |
Other Revenue | - | - | 56.83 | 56.21 | 53.63 | 61.06 |
| 15,965 | 15,964 | 16,176 | 15,457 | 13,809 | 12,802 | |
Revenue Growth (YoY) | -1.50% | -1.31% | 4.65% | 11.93% | 7.86% | 18.66% |
Cost of Revenue | 11,923 | 11,816 | 11,655 | 11,443 | 10,446 | 9,826 |
Gross Profit | 4,042 | 4,148 | 4,521 | 4,013 | 3,363 | 2,976 |
Selling, General & Admin | 3,172 | 3,226 | 3,390 | 3,143 | 2,565 | 2,306 |
Research & Development | 140.91 | 145.01 | 136.43 | 106.02 | 115.81 | 97.73 |
Other Operating Expenses | 48.97 | 46.82 | 108.29 | 120.17 | 122.65 | 113.17 |
Operating Expenses | 3,362 | 3,418 | 3,671 | 3,395 | 2,805 | 2,528 |
Operating Income | 680.23 | 730.51 | 849.71 | 618.44 | 557.91 | 447.79 |
Interest Expense | - | - | -60.07 | -56.47 | -85.53 | -105.16 |
Interest & Investment Income | - | - | 49.47 | 51.58 | 69.19 | 16.5 |
Currency Exchange Gain (Loss) | - | - | -5.68 | -5.37 | 3 | 1.99 |
Other Non Operating Income (Expenses) | -143.3 | -129.88 | 66.61 | -22.74 | -19.44 | -5.07 |
EBT Excluding Unusual Items | 536.93 | 600.62 | 900.04 | 585.45 | 525.13 | 356.06 |
Gain (Loss) on Sale of Investments | -0.77 | -0.77 | - | - | -20 | - |
Gain (Loss) on Sale of Assets | 2.52 | 3.83 | 0.94 | 0.98 | 161.38 | 210.87 |
Asset Writedown | -31.19 | -30.95 | -59.84 | -15.13 | -32.52 | -2.33 |
Other Unusual Items | - | - | 33.87 | 79.25 | 67.17 | 65.93 |
Pretax Income | 507.49 | 572.74 | 875.01 | 650.54 | 701.15 | 630.53 |
Income Tax Expense | 166.37 | 173.96 | 184.4 | 176.32 | 188.94 | 220.69 |
Earnings From Continuing Operations | 341.12 | 398.78 | 690.61 | 474.22 | 512.21 | 409.85 |
Minority Interest in Earnings | -31.32 | -37.18 | -61.76 | -78.95 | -47.06 | -38.76 |
Net Income | 309.8 | 361.6 | 628.85 | 395.26 | 465.15 | 371.08 |
Net Income to Common | 309.8 | 361.6 | 628.85 | 395.26 | 465.15 | 371.08 |
Net Income Growth | -53.42% | -42.50% | 59.10% | -15.02% | 25.35% | - |
Shares Outstanding (Basic) | 2,589 | 2,583 | 2,515 | 2,470 | 2,448 | 2,474 |
Shares Outstanding (Diluted) | 2,589 | 2,583 | 2,515 | 2,470 | 2,584 | 2,474 |
Shares Change (YoY) | 1.54% | 2.68% | 1.82% | -4.40% | 4.46% | -1.29% |
EPS (Basic) | 0.12 | 0.14 | 0.25 | 0.16 | 0.19 | 0.15 |
EPS (Diluted) | 0.12 | 0.14 | 0.25 | 0.16 | 0.18 | 0.15 |
EPS Growth | -54.12% | -44.00% | 56.25% | -11.11% | 20.00% | - |
Free Cash Flow | 565.95 | 288.71 | 691.69 | 863.14 | 532.45 | -239.13 |
Free Cash Flow Per Share | 0.22 | 0.11 | 0.28 | 0.35 | 0.21 | -0.10 |
Gross Margin | 25.32% | 25.99% | 27.95% | 25.96% | 24.35% | 23.24% |
Operating Margin | 4.26% | 4.58% | 5.25% | 4.00% | 4.04% | 3.50% |
Profit Margin | 1.94% | 2.27% | 3.89% | 2.56% | 3.37% | 2.90% |
Free Cash Flow Margin | 3.55% | 1.81% | 4.28% | 5.58% | 3.86% | -1.87% |
EBITDA | 912.68 | 959.73 | 1,066 | 878.27 | 821.32 | 716.99 |
EBITDA Margin | 5.72% | 6.01% | 6.59% | 5.68% | 5.95% | 5.60% |
D&A For EBITDA | 232.45 | 229.22 | 216.29 | 259.83 | 263.41 | 269.2 |
EBIT | 680.23 | 730.51 | 849.71 | 618.44 | 557.91 | 447.79 |
EBIT Margin | 4.26% | 4.58% | 5.25% | 4.00% | 4.04% | 3.50% |
Effective Tax Rate | 32.78% | 30.37% | 21.07% | 27.10% | 26.95% | 35.00% |
Revenue as Reported | - | - | 16,176 | 15,457 | 13,809 | 12,802 |
Advertising Expenses | - | - | 1,806 | 1,574 | 1,058 | 340.89 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.